<DOC>
	<DOCNO>NCT00001442</DOCNO>
	<brief_summary>Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization . Irradiation tumor involve node use 4-6 MV photon ( brachytherapy allow boost primary tumor ; electron allow boost posterior neck massive adenopathy ) ; plus Paclitaxel ( Bristol-Myers ) , Taxol , TAX , NSC-125973 .</brief_summary>
	<brief_title>A Pilot Study Paclitaxel With Radiation Therapy Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>This pilot study design evaluate toxicity five day infusion Paclitaxel concurrent radiation therapy advance head neck cancer . Patients previously untreated Stage III IV squamous cell cancer ( SCC ) oral cavity , oropharynx , hypopharynx , nasopharynx , larynx maxillary sinus , well Stage II SCC base tongue , nasopharynx , maxillary sinus eligible . Radiation therapy deliver 180 cGy per day total dose 6660-7200 cGy . Individual neck node boost electron 7600 cGy . Patients also receive Paclitaxel continuous IV infusion 120 mg/m ( 2 ) 120 hour central venous catheter . Tolerance regimen judge use RTOG CTEP standard toxicity criterion follow median elapse treatment time . Serial tumor biopsy obtain measure follow parameter : tumor potential doubling time ( Tpot ) , paclitaxel level tumor , biological effect upon cell cycle .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>INCLUSION CRITERIA Patients must satisfy follow criterion : The patient must biopsy proven diagnosis carcinoma oral cavity , oropharynx , hypopharynx , nasopharynx , larynx , maxillary sinus . Squamous cell , lymphoepithelioma , transitional cell undifferentiated histology include . We accept AJCC stage IIIIV site , except base tongue , nasopharynx , maxillary sinus accept stage II patient well . Patients must surgical option refuse surgery . Patients evidence distant metastasis confine region head neck exclude . All patient evaluate either NIH National Naval Medical Center ( NNMC ) Otolaryngologyhead neck surgery center . Patients must prior radiotherapy head neck region prior treatment chemotherapy head neck cancer . Patients must performance status less equal 2 ( ECOG Criteria ) . Patients must absolute granulocyte count great equal 2000/mm ( 3 ) platelet count great equal 100,000/mm ( 3 ) . Patients adequate hepatic renal function indicate serum bilirubin less equal 2.0 mg/dl SGOT le equal 4.0 time upper limit institutional norm serum creatinine less equal 1.5 mg/dl . No serious concurrent medical psychiatric illness would jeopardize ability patient receive reasonable safety chemotherapy radiation therapy outline protocol allow . No active , concomitant malignancy curatively treat carcinoma situ cervix basal cell carcinoma skin allow . Patients must least 18 year old . Signed informed consent : Each patient must aware neoplastic nature his/her disease willingly consent informed procedure follow , experimental nature therapy , alternative , potential benefit , side effect , risk , discomfort . Pregnant woman nurse mother ineligible . Eligible patient childbearing potential use contraception . Patients register protocol telephone . An authorized physician telephone information concern potential candidate protocol Orkand personnel Central Clinical Data Management Registration Office ( 301 ) 4021732 hour 8:30 5:00 pm Monday Friday .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2004</verification_date>
	<keyword>Taxol</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Radiosensitizer</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Tumor Potential Doubling Time ( Tpot )</keyword>
</DOC>